Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount

Pfizer
This week, Pfizer launched its third biosimilar and second in two months. (Pfizer)

After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching anemia treatment Retacrit at a significant discount to Amgen’s Epogen and Johnson & Johnson’s Procrit.

Pfizer started shipping Retacrit to wholesalers on Monday at a list price of $11.03 per 1,000 units/mL, a 57% discount to Procrit and a 33.5% discount to Epogen. Together, Epogen and Procrit—which share the same active ingredient but are marketed for different uses under an Amgen-J&J licensing agreement—pulled in $1.77 billion in the U.S. last year.

The drugmaker won FDA approval for Retacrit in May after two previous complete response letters from the agency, the first seeking more data and the second over manufacturing issues.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Retacrit’s launch closely follows Pfizer’s rollout for Nivestym after an approval in July. The New York drugmaker launched Nivestym starting in October at a 30% discount to Amgen’s Neupogen, a spokesperson said. In both cases, Pfizer pointed out that the wholesale price doesn't reflect rebates and discounts.

RELATED: The top 15 drug patent expirations of 2018 - Epogen/Procrit

Pfizer’s latest pricing moves mark somewhat of a strategy shift from its Inflectra rollout, a biosimilar to Johnson & Johnson’s Remicade. The company introduced that biosimilar back in 2016 at a 15% discount to the brand. Uptake for the biosimilar has been slower than expected, and Pfizer has sued J&J for “anticompetitive” contracting to protect the brand.

In the third quarter, Inflectra generated $166 million worldwide, compared with Remicade’s $1.38 billion.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.